Journal of Medicinal Chemistry · 2016 · 17 citations · 23 references
PharmacyBiochemistryMedicinal ChemistryDrug DesignDrug DiscoveryStructural BiologyFragment-based Drug DesignFragment-based Lead DiscoveryLigand BindingProtein BindingProtein StructureProtein-ligand BindingDruggable Target DiscoveryFatty Acid BindingFragment-based DiscoveryFragment-based Ligand DesignProtein TargetsStructure-based ScreeningStructure-guided Lead DiscoverySurface Plasmon Resonance Analysis
Fatty acid binding protein 6 (FABP6) is a potential drug discovery target, which, if inhibited, may have a therapeutic benefit for the treatment of diabetes. Currently, there are no published inhibitors of FABP6, and with the target believed to be amenable to fragment-based drug discovery, a structurally enabled program was initiated. This program successfully identified fragment hits using the surface plasmon resonance (SPR) platform. Several hits were validated with SAR and were found to be displaced by the natural ligand taurocholate. We report the first crystal structure of human FABP6 in the unbound form, in complex with cholate, and with one of the key fragments.
23
Features and development of <i>Coot</i>
Paul Emsley, Bernhard Lohkamp, W. G. Scott et al. · Acta Crystallographica Section D Biological Crystallography · 2010 · 29.6K citations · Full text
<i>Phaser</i>crystallographic software
Airlie J. McCoy, Ralf W. Grosse‐Kunstleve, Paul D. Adams et al. · Journal of Applied Crystallography · 2007 · 20.9K citations · Full text
Wolfgang Kabsch · Acta Crystallographica Section D Biological Crystallography · 2010 · 16.9K citations · Full text
Overview of the<i>CCP</i>4 suite and current developments
Martyn Winn, Charles Ballard, Kevin Cowtan et al. · Acta Crystallographica Section D Biological Crystallography · 2011 · 12.6K citations · Full text